High Risk/Recurrent/Advanced Prostate Cancer Virtual Group recording – 02/11/20

High Risk/Recurrent/Advanced Prostate Cancer Virtual Group recording – 02/11/20

Topics discussed:

Editor’s Pick – ATM and TP53 mutations may increase risk of radiation damage.

Treatment after 2nd line anti-androgen fails; CARD trial & Jevtana/cabazitaxel; finding a trial close to home; is chemo best early or late?; somatic mutations can change; osteopenia – what to do; ADT driven anemia; ATM & TP53 mutations may increase risk for radiation damage; dealing with pain before and after cancer Dx

Chatlog

Jake (to Everyone): 4:22 PM: https://clinicaltrials.gov/ct2/show/NCT03725761

Jake (to Everyone): 4:38 PM: https://clinicaltrials.gov/ct2/show/NCT03725761

Jake (to Everyone): 5:35 PM: https://www.youtube.com/watch?v=B9bDZ5-zPtY

Ken Anderson (to Everyone): 5:36 PM: thanks Jake

Jake (to Organizer(s) Only): 5:39 PM: William li video I thnk we just discussed

Under-60 Advanced Prostate Cancer

Under-60 Advanced Prostate Cancer

Back in mid-2012, the US Preventative Services Task Force first made the following recommendation with an associated D Grade:
The U.S. Preventive Services Task Force (USPSTF) recommends against prostate-specific antigen (PSA)–based screening for prostate cancer.

 At the time, prostate cancer advocates objected strongly, warning it would result in many more men diagnosed de novo metastatic, and ultimately more disease specific deaths.

Sadly, we have seen this manifested, especially with respect to younger men. AnCan clearly sees the trend along with a lack of support for the particular needs expressed by younger men living with advanced prostate cancer. Along with our  partner, UsTOO, we have established an Under-60 Advanced Prostate Cancer Virtual Group to address these needs.
——————————————————————————————————–

2nd Thursday of each month at 7 pm Eastern in The Barniskis Room (222-583-973)

Under-60 Advanced Prostate Cancer

Under-60 Advanced Prostate Cancer

Back in mid-2012, the US Preventative Services Task Force first made the following recommendation with an associated D Grade:
The U.S. Preventive Services Task Force (USPSTF) recommends against prostate-specific antigen (PSA)–based screening for prostate cancer.

 At the time, prostate cancer advocates objected strongly, warning it would result in many more men diagnosed de novo metastatic, and ultimately more disease specific deaths.

Sadly, we have seen this manifested, especially with respect to younger men. AnCan clearly sees the trend along with a lack of support for the particular needs expressed by younger men living with advanced prostate cancer. Along with our  partner, UsTOO, we have established an Under-60 Advanced Prostate Cancer Virtual Group to address these needs.
——————————————————————————————————–

2nd Thursday of each month at 7 pm Eastern in The Barniskis Room (222-583-973)

Under-60 Advanced Prostate Cancer

Under-60 Advanced Prostate Cancer

Back in mid-2012, the US Preventative Services Task Force first made the following recommendation with an associated D Grade:
The U.S. Preventive Services Task Force (USPSTF) recommends against prostate-specific antigen (PSA)–based screening for prostate cancer.

 At the time, prostate cancer advocates objected strongly, warning it would result in many more men diagnosed de novo metastatic, and ultimately more disease specific deaths.

Sadly, we have seen this manifested, especially with respect to younger men. AnCan clearly sees the trend along with a lack of support for the particular needs expressed by younger men living with advanced prostate cancer. Along with our  partner, UsTOO, we have established an Under-60 Advanced Prostate Cancer Virtual Group to address these needs.
——————————————————————————————————–

2nd Thursday of each month at 7 pm Eastern in The Barniskis Room (222-583-973)

Under-60 Advanced Prostate Cancer

Under-60 Advanced Prostate Cancer

Back in mid-2012, the US Preventative Services Task Force first made the following recommendation with an associated D Grade:
The U.S. Preventive Services Task Force (USPSTF) recommends against prostate-specific antigen (PSA)–based screening for prostate cancer.

 At the time, prostate cancer advocates objected strongly, warning it would result in many more men diagnosed de novo metastatic, and ultimately more disease specific deaths.

Sadly, we have seen this manifested, especially with respect to younger men. AnCan clearly sees the trend along with a lack of support for the particular needs expressed by younger men living with advanced prostate cancer.
——————————————————————————————————–

2nd Thursday of each month at 7 pm Eastern in The Barniskis Room (222-583-973)